Page 100 - 88_01
P. 100
B, et al.. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib ANALES
and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. RANF
2000;343(21):1520–8.
9. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton www.analesranf.com
A, et al.. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal
Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-
The CLASS Study: A Randomized Controlled Trial Fred. JAMA. inflammatory drugs: network meta-analysis. BMJ.
2000;284(10):1247–55. 2011;342(1):c7086.
10. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty 20. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, et al..
M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen Cardiovascular risk associated with celecoxib or etoricoxib: a meta-
and ibuprofen in the Therapeutic Arthritis Research and Gas- analysis of randomized controlled trials which adopted comparison
trointestinal Event Trial (TARGET), reduction in ulcer complications: with placebo or naproxen. Minerva Cardioangiol. 2014;62:437–8.
Randomised controlled trial. Lancet. 2004;364(9435):665–74. 21. McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclo-
11. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison oxygenase. JAMA. 2006;296(13):1633.
of gastrointestinal adverse effects between cyclooxygenase-2 in- 22. Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane
hibitors and non-selective, non-steroidal anti- inflammatory drugs L, et al.. Meta-Analysis: Cardiovascular Events Associated with Nons-
plus proton pump inhibitors: A systematic review and meta-analysis. teroidal Anti-inflammatory Drugs. Am J Med. 2006;119(7):552–
J Gastroenterol. 2013;48(7):830–8. 9.
12. Watson D, Yu Q, Bolognese J, Reicin A, Simon T. The upper gas- 23. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-
trointestinal safety of rofecoxib vs. NSAIDs: an updated inflammatory drugs: Systematic review of population-based
combined analysis. Curr Med Res Opin. controlled observational studies. PLoS Med.
2004;20(10):1539–48. 2011;8(9):e1001098.
13. Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The 24. European Medicines Agency. European Medicines Agency - News
incidence of upper gastrointestinal adverse events in clinical trials and Events - PRAC recommends updating advice on use of high-
of etoricoxib vs. non-selective NSAIDs: an updated combined analy- dose ibuprofen [Internet]. Disponible en:
sis. Curr Med Res Opin. 2005;21(5):715–22. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and
14. Wang X, Tian HJ, Yang HK, Wanyan P, Peng YJ. Meta-analysis: _events/news/2015/04/news_d
Cyclooxygenase-2 inhibitors are no better than nonselective nons- etail_002306.jsp&mid=WC0b01ac058004d5c1. [Accedido el 16
teroidal anti-inflammatory drugs with proton pump inhibitors in re- Jul 2021].
gard to gastrointestinal adverse events in osteoarthritis and 25. Sondergaard KB, Weeke P, Wissenberg M, Schjerning Olsen A-M,
rheumatoid arthritis. Eur J Gastroenterol Hepatol. Fosbol EL, Lippert FK, et al.. Non-steroidal anti-inflammatory drug
2011;23(10):876–80. use is associated with increased risk of out-of- hospital cardiac arrest:
15. Zeng C, Wei J, Li H, Yang T, Gao SG, Li YS, et al.. Comparison bet- a nationwide case–time–control study. Eur Hear J - Cardiovasc
ween 200mg QD and 100mg BID oral celecoxib in the treatment Pharmacother. 2017;3:100-7.
of knee or hip osteoarthritis. Sci Rep. 2015;5(January):1–13. 26. Wells G, Shea B, O ’connell D, Robertson J, Peterson J, Welch V, et
16. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myo- al. The Newcastle- Ottawa Scale (NOS) for Assessing the Quality
cardial infarction with nonselective non-steroidal anti-inflamma- of Nonrandomized Studies in Meta- Analysis [Internet]. Disponible
tory drugs: a meta-analysis. Arthritis Res Ther.2006;8(2):R153. en: http://www.evidencebasedpublichealth.de/download/Newcas-
17. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan tle_Ottowa_Scale_Pope_Bruce.p df. [Accedido el 16 Jul 2021].
K, et al.. Cardiovascular Events Associated with Rofecoxib in a Co- 27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
lorectal Adenoma Chemoprevention Trial. N Engl J Trials. 1986;7(3):177–88.
Med.2005;352(11):1092–102. 28. Higgins JPT, Green S. Manual Cochrane de revisiones sistemá-
18. Solomon SD, Wittes J, Finn P V., Fowler R, Viner J, Bertagnolli MM, ticas de intervenciones. Cochrane. 2011; (March):1–639
et al.. Cardiovascular risk of celecoxib in 6 randomized placebo-con- [Internet]. Disponible en: https://es.cochrane.org/sites/es.coch-
trolled trials: The cross trial safety analysis. Circulation. rane.org/files/public/uploads/manual_cochrane_510_web. pdf.
2008;117(16):2104–13. [Accesed 16 Jul 2021].
19. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen 29. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta- analyses. BMJ. 2003;327(7414):557-60.
30. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629-
34.
31. Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S,
Analysis and evaluation of cardiovascular and gastrointestinal risk of nonsteroidal
98 anti-inflammatory drugs selective and non-selective cyclooxygenase inhibitors
Antonio Margo
An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103
